Devi SenGupta

发表

Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials

D. Podzamczer, E. Negredo, H. Stellbrink, 2019, AIDS.

Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial.

M. Das, J. Lelièvre, J. Slim, 2019, The lancet. HIV.

Consistent Cytotoxic-T-Lymphocyte Targeting of Immunodominant Regions in Human Immunodeficiency Virus across Multiple Ethnicities

F. M. Marincola, Nicole Frahm, B. Walker, 2004, Journal of Virology.

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.

O. Tsang, G. Criner, M. Mcphail, 2020, JAMA.

Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021

J. Nabukenya, T. Ndung’u, S. Lewin, 2021, Nature Medicine.

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

R. Bruno, K. Tashima, D. Hui, 2020, The New England journal of medicine.

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial

K. White, H. Stellbrink, P. Sax, 2017, The Lancet.

Anti-HERV-K (HML-2) capsid antibody responses in HIV elite controllers

Jeffrey N. Martin, D. Nixon, F. Hecht, 2017, Retrovirology.

HERV-K-specific T cells eliminate diverse HIV-1/2 and SIV primary isolates.

Nabil F. Faruk, D. Nixon, M. Ostrowski, 2012, The Journal of clinical investigation.

Human Endogenous Retrovirus Expression Is Inversely Associated with Chronic Immune Activation in HIV-1 Infection

Steven G. Deeks, Mario A. Ostrowski, R. Brad Jones, 2012, PloS one.

Identification of Human Endogenous Retrovirus-Specific T Cell Responses in Vertically HIV-1-Infected Subjects

D. Nixon, M. Ostrowski, R. B. Jones, 2011, Journal of Virology.

Strong Human Endogenous Retrovirus-Specific T Cell Responses Are Associated with Control of HIV-1 in Chronic Infection

Jeffrey N. Martin, D. Nixon, M. Ostrowski, 2011, Journal of Virology.

HIV & Hepatitis in the Americas 28–30 April 2016, Mexico City, Mexico

N. Volkow, K. Tashima, D. Podzamczer, 2016, Journal of the International AIDS Society.

Relative mRNA Expression Levels of Restriction Factors and Antiviral Genes in Fetal and Adult Human Monocytes and Monocyte-Derived Macrophages.

J. McCune, W. Yonemoto, D. SenGupta, 2017, Viral immunology.

Cutting Edge: An Antibody Recognizing Ancestral Endogenous Virus Glycoproteins Mediates Antibody-Dependent Cellular Cytotoxicity on HIV-1–Infected Cells

Jeffrey N. Martin, D. Nixon, S. Deeks, 2014, The Journal of Immunology.

Trans-activation, post-transcriptional maturation, and induction of antibodies to HERV-K (HML-2) envelope transmembrane protein in HIV-1 infection

Jeffrey N. Martin, D. Nixon, F. Hecht, 2014, Retrovirology.

Human Endogenous Retrovirus K(HML-2) Gag- and Env-Specific T-Cell Responses Are Infrequently Detected in HIV-1-Infected Subjects Using Standard Peptide Matrix-Based Screening

Theo M. Luider, Gabor Gyenes, Mario A. Ostrowski, 2011, Clinical and Vaccine Immunology.

Cytotoxicity on HIV-1 Mediates Antibody-Dependent Cellular Ancestral Endogenous Virus Glycoproteins Cutting Edge: An Antibody Recognizing

Jeffrey N. Martin, D. Nixon, S. Deeks, 2014 .

The CD8+ Memory Stem T Cell (TSCM) Subset Is Associated with Improved Prognosis in Chronic HIV-1 Infection

D. Nixon, S. Deeks, J. Kalil, 2014, Journal of Virology.

D. Nixon, L. Ndhlovu, M. T. Giret, 2012, PloS one.

p16INK4a Expression and Immunologic Aging in Chronic HIV Infection

Susan Pereira Ribeiro, Jorge Kalil, D. Nixon, 2016, PloS one.

Resistance Analysis of Bictegravir-Emtricitabine-Tenofovir Alafenamide in HIV-1 Treatment-Naive Patients through 48 Weeks

K. White, Ross Martin, D. SenGupta, 2019, Antimicrobial Agents and Chemotherapy.

Multi-stakeholder consensus on a target product profile for an HIV cure

T. Ndung’u, M. Dybul, S. Lewin, 2020, The lancet. HIV.

Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial

R. Paredes, B. Clotet, R. Geleziunas, 2022, Nature Medicine.

Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study

K. Lichtenstein, F. Post, Samir K. Gupta, 2016, Journal of acquired immune deficiency syndromes.

Heat Shock Protein-Mediated Cross-Presentation of Exogenous HIV Antigen on HLA Class I and Class II1

B. Walker, C. Brander, A. Trocha, 2004, The Journal of Immunology.

Antigen on HLA Class I and Class II Cross-Presentation of Exogenous HIV Heat Shock Protein-Mediated

B. Walker, C. Brander, A. Trocha, 2004 .

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.

A. LaMarca, D. Podzamczer, A. Lazzarin, 2017, The lancet. HIV.

The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy

T. Wrin, J. Mellors, R. Begley, 2021, Science Translational Medicine.

Strong Human Endogenous Retrovirus-Speciﬁc T Cell Responses Are Associated with Control of HIV-1 in Chronic Infection (cid:1) †‡

Jeffrey N. Martin, D. Nixon, M. Ostrowski, 2011 .

Age but not disease progression defines CD4+ and CD8+ T stem cell memory levels in human retroviral infections: contrasting effects of HTLV-1 and HIV-1

D. Nixon, M. Roederer, S. Ribeiro, 2018, bioRxiv.